New initiative is under way to strengthen community leadership and mobilization toward ambitious HIV prevention and treatment goals against the backdrop of anticipated shifts in federal support and resources for critical programs.
New Report Shines Spotlight on Need for More Investments in Community Leadership and Mobilization to End HIV as an Epidemic January 9, 2017 – The success of recent local and state initiatives to end HIV as an epidemic will hinge…
The first goal of the National HIV/AIDS Strategy (NHAS) is to “reduce new infections.” In order to monitor progress toward this goal, the Centers for Disease Control and Prevention (CDC) and the Office of National AIDS Policy will be looking…
TAG's annual review of progress we've made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.
A coalition of HIV/AIDS activists are calling for renewed attention to HIV-positive people termed immunologic non-responders (INRs), who experience suboptimal immune system reconstitution despite years of viral load suppression by antiretroviral therapy. Studies have shown that INR patients remain at increased risk of illness and death compared to HIV-positive people who have better restoration of immune function on current drug therapies.
November 2016 Examples of media coverage: Israeli scientists see breakthrough in AIDS cure – The Times of Israel, November 1, 2016 Israeli researchers offer some hope for HIV carriers – Arutz Sheva 7, November 1, 2016 Israeli research successful in…
Dear Minority Leader Pelosi: On behalf of Treatment Action Group (TAG), I write to you strongly urging for the reconsideration of your support for the passage of the 21st Century Cures Act. Even as an impending and new version of the bill is set to be introduced by Energy and Commerce Chairman, Rep. Fred Upton – we are concerned that several provisions carried from the prior iteration of the bill (H.R. 6) may continue to undermine public health and jeopardize patient safety. These concerns include lowering standards for the FDA in determining approval for prospective drugs and devices, increasing the likelihood of antimicrobial resistance, to granting extended market exclusivity for new drugs.
Health, Human Rights, and Social Justice: maximizing HIV, tuberculosis (TB), and viral hepatitis outcomes depends on the availability of state-of-the-art diagnostic and prognostic tools, engagement in expert and supportive care, and access to safe and effective drugs.
We will not end HIV as an epidemic without the expertise and leadership of Black and Latino gay and bisexual men and transgender people of color. By Jeremiah Johnson In February 2016, the CDC issued a new report with a…
Upholding narratives of Black science and treatment activism, and community mobilization in HIV/AIDS and TB By Suraj Madoori In February 2016, startling data released by the Centers for Disease Control and Prevention (CDC) at the Conference of Retroviruses and Opportunistic…